Neogen Corp Dossier
|
SectorHealth Care IndustryMedical Devices Beta (adjusted)1.53 Intrinsic Value $15.59median of 3 methodsbased on filings through 31 May 2026 Market Price $12.24Price as of 1 Oct 2026 UndervaluedIntrinsic value is 27% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $2.7B Enterprise Value $3.3B Shares Outstanding 217.5M diluted Moat Rating None Next Earnings Date6 Oct 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Neogen Corporation is currently navigating a complex operational turnaround following its transformative 2022 merger with 3M's Food Safety Division. While the integration has historically pressured margins and cash flows, the company is approaching a critical inflection point under the leadership of CEO Mike Nassif. Key structural improvements are underway, including the transition of high-margin Petrifilm manufacturing in-house (targeted for November 2026) and portfolio optimization through the divestiture of the Genomics business to Zoetis for $160 million. However, near-term headwinds persist, particularly supplier-related disruptions in the Animal Safety segment and a leveraged balance sheet. A Hold recommendation is advised until the Petrifilm transition is fully executed and top-line momentum stabilizes across both core segments. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$12.00 Mean target$13.00 High · most bullish analyst$14.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $12.00 The bear case is characterized by delays in the Petrifilm transition beyond November 2026, prolonging duplicative manufacturing costs and depressing gross margins. Persistent third-party supplier disruptions continue to drag down the Animal Safety segment, while integration complexities or regulatory hurdles delay the Genomics divestiture, keeping leverage elevated and restricting free cash flow generation. Base CaseCentral scenario $13.00 Matches the consensus meanThe base case assumes steady progress on the Petrifilm transition with full completion by November 2026, allowing gradual margin recovery. The Genomics divestiture closes on schedule in Q2 FY2027, providing $140 million in net proceeds to pay down debt. Food Safety core growth remains stable at 3-5%, while Animal Safety supplier issues are resolved over the next two quarters, leading to flat-to-slightly positive core growth in that segment. Bull CaseUpside scenario $14.00 The bull case is driven by rapid execution of the Petrifilm manufacturing transition, which eliminates duplicative costs and expands adjusted gross margins toward historical levels above 53%. Additionally, swift completion of the Genomics divestiture accelerates deleveraging, bringing net debt-to-adjusted EBITDA below 3.0x by the end of calendar year 2026. Strong secular tailwinds in food safety diagnostics and successful global go-to-market realignment drive double-digit core growth. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |